Drugs “R” Us
Practice this intermediate merger & acquisition case interview question in the Healthcare sector. Includes detailed problem prompt, clarifying questions, structured framework, and expert recommendation. Part of ProHub's 835+ consulting case library.
This is a structured M&A case requiring candidates to build a revenue-focused framework and perform quantitative analysis. The key insight is recognizing that the acquisition adds only ~$1.8B in pharmaceutical revenue against a target of ~$16.1B (20% growth on RX Co's ~$14B baseline), making the deal insufficient on its own. Strong candidates distinguish between total US stores and NW region stores, explore revenue sources (RX vs. Front-of-House Merchandise), and identify strategic risks beyond pure financials.
Clarifying Information
- RX Co aims to grow annual revenue by 20% from current levels. They want this to happen the first year after the acquisition is complete. Assume the acquisition can be completed and the assets operational in one year.